Clopidogrel dosing and role of genetics: ELEVATE-TIMI 56 trial: Difference between revisions

Revision as of 14:45, 25 November 2011

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.B.B.S. [2]

The results of the ELEVATE-TIMI 56 trial were recently presented in AHA 2011 held at Orlando, Florida.

Hypothesis -
Study design
- Patient population
  - Multicenter, randomized, double-blind trial
  - Duration of study - 1 years
  - Intervention -
  - Primary end point -

@@ Line 4: / Line 4: @@
 The results of the '''ELEVATE-TIMI 56 trial''' were recently presented in [[AHA]] 2011 held at Orlando, Florida.
-<ref name="pmid22088980">{{cite journal| author=Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ et al.| title=Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. | journal=JAMA | year= 2011 | volume= 306 | issue= 20 | pages= 2221-8 | pmid=22088980 | doi=10.1001/jama.2011.1703 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22088980  }} </ref>==ELEVATE-TIMI 56 trial ==
+==ELEVATE-TIMI 56 trial <ref name="pmid22088980">{{cite journal| author=Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ et al.| title=Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. | journal=JAMA | year= 2011 | volume= 306 | issue= 20 | pages= 2221-8 | pmid=22088980 | doi=10.1001/jama.2011.1703 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22088980  }} </ref> ==
 * '''Hypothesis''' -